Extra domain A-containing fibronectin in pulmonary hypertension and treatment effects of a function-blocking antibody [0.03%]
肺动脉高压患者血浆中额外的A型含纤维连接蛋白结构域蛋白及功能阻断抗体治疗效果研究
Isabell Singerer,Laura Tempel,Katja Gruen et al.
Isabell Singerer et al.
Aims: Pulmonary vascular and right ventricular (RV) remodelling processes are important for development and progression of pulmonary hypertension (PH). The current study analysed the functional role of the extra domain A-...
Beneficial normalization of cardiac repolarization by carnitine in transgenic short QT syndrome type 1 rabbit models [0.03%]
左旋肉碱对短QT综合症1型转基因兔模型心脏复极化有益的调控作用
Ilona Bodi,Lea Mettke,Konstantin Michaelides et al.
Ilona Bodi et al.
Aims: Short QT syndrome type 1 (SQT1) is a genetic channelopathy caused by gain-of-function variants in human-ether-a-go-go (HERG) underlying the rapid delayed-rectifier K+ current (IKr), leading to QT-shortening, ventric...
Genetic deletion or pharmacologic inhibition of histone deacetylase 6 protects the heart against ischaemia/reperfusion injury by limiting tumour necrosis factor alpha-induced mitochondrial injury in experimental diabetes [0.03%]
遗传学缺失或药理抑制组蛋白去乙酰酶6通过限制肿瘤坏死因子α诱导的线粒体损伤来保护糖尿病缺血再灌注损伤的心脏
Shelley L Baumgardt,Juan Fang,Xuebin Fu et al.
Shelley L Baumgardt et al.
Aims: The histone deacetylase 6 (HDAC6) inhibitor, tubastatin A (TubA), reduces myocardial ischaemia/reperfusion injury (MIRI) in type 1 diabetic rats. It remains unclear whether HDAC6 regulates MIRI in type 2 diabetic an...
Przemysław Mitkowski,Adam Witkowski,Piotr Szymański et al.
Przemysław Mitkowski et al.
Beyond the numbers in treating hypertensive end-organ damage: role of formyl peptide receptor agonist Cmpd17b [0.03%]
治疗高血压靶器官损害 beyond the numbers——形式肽受体激动剂Cmpd17b的作用
Claude F Albritton,Antentor Hinton,Annet Kirabo
Claude F Albritton
Advances in nucleic acid-targeted therapies for cardiovascular disease prevention [0.03%]
心血管疾病预防的核酸靶向治疗研究进展
Umidakhon Makhmudova,Elisabeth Steinhagen-Thiessen,Massimo Volpe et al.
Umidakhon Makhmudova et al.
Nucleic acid-based therapies are being rapidly developed for prevention and management of cardiovascular diseases (CVD). Remarkable advancements have been achieved in the delivery, safety, and effectiveness of these therapeutics in the past...
How to be a good mentor [0.03%]
如何成为一个优秀的导师
Stefan Neubauer
Stefan Neubauer
The promise of gene therapy in hypertrophic cardiomyopathy: emergence of human experience [0.03%]
梗阻性肥厚心肌病基因治疗的前景——人类研究结果初探
Milind Y Desai
Milind Y Desai
Single-nucleus transcriptomics reveals adrenergic and STAT3 signaling in paradoxical low-flow low-gradient -specific cardiomyocyte subclusters: implications for aortic stenosis pathogenesis and treatment [0.03%]
单核转录组学揭示肾上腺素能和STAT3信号传导在矛盾的低流量低梯度特异性心肌细胞亚簇中的作用：对主动脉瓣狭窄发病机制和治疗的意义
Xingbo Xu,Xiaoying Tan,Baolong Cui et al.
Xingbo Xu et al.